Holen Sie sich die Stockscreener-App
167.03
2.97%
-5.11
Handel nachbörslich:
166.00
-1.03
-0.62%
Schlusskurs vom Vortag:
$172.14
Offen:
$172.47
24-Stunden-Volumen:
725.26K
Relative Volume:
0.80
Marktkapitalisierung:
$8.22B
Einnahmen:
$4.06B
Nettoeinkommen (Verlust:
$413.08M
KGV:
20.85
EPS:
8.01
Netto-Cashflow:
$560.48M
1W Leistung:
-5.81%
1M Leistung:
+8.98%
6M Leistung:
+67.11%
1J Leistung:
-12.75%
1-Tages-Spanne:
$166.93
$174.37
1-Wochen-Bereich:
$166.93
$179.64
52-Wochen-Spanne:
$91.86
$230.02
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Vergleichen Sie CRL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
167.03 | 8.47B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
524.80 | 201.90B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
202.46 | 146.42B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
616.15 | 50.30B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
136.62 | 39.72B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
198.17 | 34.51B | 15.70B | 1.24B | 2.01B | 6.9036 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-06 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-09-09 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-23 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-05-08 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-03 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Why Charles River Laboratories International Inc. (RV6) stock is trending on social mediaGlobal Markets & Community Trade Idea Sharing Platform - newser.com
Published on: 2025-10-10 13:12:55 - newser.com
Why Charles River Laboratories International Inc. stock is seen as undervaluedExit Point & Expert Approved Momentum Ideas - newser.com
Can Charles River Laboratories International Inc. stock deliver strong Q4 earningsWeekly Risk Report & AI Powered Buy and Sell Recommendations - newser.com
Weiss Ratings Reiterates "Sell (D)" Rating for Charles River Laboratories International (NYSE:CRL) - MarketBeat
Charles River Laboratories International Inc. stock prediction for this weekCPI Data & Expert Approved Momentum Ideas - newser.com
Published on: 2025-10-09 06:30:08 - newser.com
Does Charles River Laboratories International Inc. (RV6) stock trade below intrinsic valueQuarterly Earnings Summary & Real-Time Volume Analysis - newser.com
Is Charles River Laboratories International Inc. (RV6) stock positioned for digital growth eraInsider Buying & Stock Portfolio Risk Control - newser.com
Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicity Testing - BioSpace
Winners And Losers Of Q2: Charles River Laboratories (NYSE:CRL) Vs The Rest Of The Drug Development Inputs & Services Stocks - FinancialContent
What drives Charles River Laboratories International Inc stock priceMorning Star Patterns & High Yield Portfolio Picks - earlytimes.in
Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicit - PharmiWeb.com
Charles River, Toxys Form Partnership on Use of Drug Toxicity Detection Tool - MarketScreener
Charles River (CRL) Partners with Toxys to Enhance Toxicity Testing - GuruFocus
Charles River Laboratories Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators - Markets Mojo
HB Wealth Management LLC Invests $306,000 in Charles River Laboratories International, Inc. $CRL - MarketBeat
State of Alaska Department of Revenue Sells 10,403 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International (NYSE:CRL) Downgraded by Wall Street Zen to Buy - MarketBeat
William Blair Upgrades Charles River Laboratories International (CRL) - Nasdaq
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch
William Blair Upgrades Charles River (CRL) to Outperform | CRL S - GuruFocus
Is now a turning point for Charles River Laboratories International Inc.Quarterly Earnings Summary & Real-Time Volume Surge Alerts - newser.com
Will Charles River Laboratories International Inc. (RV6) stock outperform benchmarks2025 Analyst Calls & Consistent Profit Trading Strategies - newser.com
Charles River Laboratories International, Inc. $CRL is Laurus Global Equity Management Inc.'s 4th Largest Position - MarketBeat
Sendero Wealth Management LLC Takes Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Published on: 2025-10-06 04:36:58 - newser.com
What institutional flow reveals about Charles River Laboratories International Inc.July 2025 Highlights & Free Risk Controlled Daily Trade Plans - newser.com
Is Charles River Laboratories International Inc a good long term investmentSector Performance Review & Reap the Rewards of Patience + Planning - earlytimes.in
Charles River Laboratories (CRL): Assessing Valuation Following Analyst Upgrades and Renewed Optimism on Demand Stability - simplywall.st
Will Charles River Laboratories International Inc. (RV6) stock sustain uptrend momentumM&A Rumor & Safe Entry Trade Reports - newser.com
Is Charles River Laboratories International Inc. stock included in top ETFs2025 Winners & Losers & Daily Growth Stock Investment Tips - newser.com
Why Analysts Believe the Story for Charles River Labs Is Shifting After Recent Strategic Moves - Yahoo Finance
Charles River Labs (CRL) Receives a Buy from Evercore ISI - The Globe and Mail
Charles River Laboratories International, Inc. $CRL Stock Holdings Cut by Wealth Enhancement Advisory Services LLC - Defense World
Charles River Laboratories (CRL): Do Analyst Upgrades Signal a Shift in Management Credibility or Market Perception? - simplywall.st
Charles River Laboratories (CRL) Stock Is Up, What You Need To Know - FinancialContent
What Do the Recent Analyst Upgrades Reveal About Charles River (CRL)’s Competitive Position? - simplywall.st
Evercore ISI Adjusts PT on Charles River Laboratories International to $200 From $190, Maintains Outperform Rating - MarketScreener
What candlestick patterns are forming on Charles River Laboratories International Inc.July 2025 Snapshot & Low Drawdown Momentum Trade Ideas - newser.com
Public Employees Retirement System of Ohio Decreases Stock Holdings in Charles River Laboratories International, Inc. $CRL - Defense World
Charles River Laboratories International (NYSE:CRL) Upgraded by Barclays to “Overweight” Rating - Defense World
Relative strength of Charles River Laboratories International Inc. in sector analysisInsider Selling & Expert-Curated Trade Recommendations - newser.com
Published on: 2025-10-02 23:58:17 - newser.com
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.17%
2.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):